Generated by AI
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes a broad portfolio of essential medicines. Its current business centers on generics, injectables, biosimilars, and specialty branded pharmaceutical products, serving patients and healthcare providers across the United States and other international markets. The company operates through three main segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment spans a wide range of dosage forms and delivery systems, including oral solids, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, and transdermal therapies. The Specialty segment focuses on branded treatments for selected therapeutic areas, while AvKARE supplies pharmaceuticals, medical, and surgical products and services to governmental agencies. Headquartered in Bridgewater, New Jersey, Amneal Pharmaceuticals plays a significant role in expanding access to cost-effective and differentiated medicines within the global pharmaceutical market.
Website400 Crossing Boulevard
Bridgewater, NJ, 08807
United States
The latest articles about AMRX.
Amneal Pharmaceuticals reported past third quarter 2026 sales of US$862.68 million with adjusted EPS ahead of analyst estimates, while management lifted full year 2026 net revenue guidance to a range of US$3.15 billion to US$3.25 billion. The latest update highlights stronger contributions from complex generics, specialty brands and biosimilars, alongside reduced asset impairment charges compared with the prior year period. We will examine how Amneal Pharmaceuticals' higher 2026 revenue...
Summary of Sep 21's posts. Generated by AI.
Summary of Aug 26's posts. Generated by AI.
Summary of Sep 21's posts. Generated by AI.
Investors talking about AMRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.